Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center

Overview of attention for article published in Frontiers in oncology, January 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 38 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 24,622 followers.

RT @FrontOncology: New research: Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Exper…

31 Jan 2022

Reply Repost Favourite

New research: Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center: Objective This study was conducted in order to compare the efficacy and safety of transarterial… https://t.co

31 Jan 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.